-
Je něco špatně v tomto záznamu ?
Improving pre-operative binary grading: relevance of p53 and PR expression in grade 2 endometrioid endometrial carcinoma
P. Meijs-Hermanns, HMJ. Werner, L. Kooreman, P. Bretová, V. Weinberger, S. Vrede, LSM. Alcala, F. Amant, J. Asberger, M. Bednaříková, D. Boll, CM. Bronkhorst, J. Bulten, A. Gil-Moreno, IS. Haldorsen, J. Hausnerová, J. Huvila, M. Koskas, C....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 2018-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2018-01-01 do Před 6 měsíci
- MeSH
- dospělí MeSH
- endometroidní karcinom * patologie metabolismus chirurgie mortalita MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery metabolismus MeSH
- nádorový supresorový protein p53 * metabolismus biosyntéza MeSH
- nádory endometria * patologie metabolismus chirurgie mortalita MeSH
- prognóza MeSH
- receptory progesteronu * metabolismus biosyntéza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stupeň nádoru MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: This study aimed to evaluate the association between pre-operative progesterone receptor (PR) and p53 expression and prognosis in pre-operative grade 2 endometrioid endometrial carcinoma compared with grade 1 and grade 3 carcinomas. METHODS: Three European endometrial carcinoma cohort studies were included. Patients with pre-operative grade 2 endometrioid carcinoma and known pre-operative PR and p53 status were included (n = 400), as were patients with pre-operative grade 1 (n = 602) or grade 3 (n = 148) endometrioid carcinomas. Kaplan-Meier and Cox regression analyses were performed to analyze disease-specific and disease-free survival. RESULTS: Patients with pre-operative grade 2 endometrial carcinoma and wild-type p53 plus PR-positive expression showed a similar 7-year disease-specific survival to grade 1 endometrial carcinoma patients (95.8% vs 97.5%, p = .13), while the 7-year disease-specific survival of patients with grade 2 endometrial carcinoma with p53 aberrant and/or negative PR expression (83.5%) was significantly lower (p < .001). The combination of these markers was an independent prognostic factor in multivariate Cox regression analyses. CONCLUSIONS: The prognostic impact of pre-operative p53 and PR expression in patients with grade 2 endometrioid endometrial carcinoma supports a modified binary grading system in which grade 2 patients should be pre-operatively classified as low- or high-grade depending on p53 and PR expression.
Amphia Hospital Department of Obstetrics and Gynecology Breda The Netherlands
Amphia Hospital Department of Pathology Breda The Netherlands
APHP Bichat Hospital Department of Obstetrics and Gynecology Paris France
Canisius Wilhelmina Hospital Department of Pathology Nijmegen The Netherlands
Catharina Hospital Department of Gynecology Eindhoven The Netherlands
CIBERONC Vall d'Hebron University Hospital Gynecological Department Barcelona Spain
Elisabeth TweeSteden Hospital Department of Gynecology Tilburg The Netherlands
Elisabeth TweeSteden Hospital Department of Pathology Tilburg The Netherlands
Elkerliek Hospital Department of Obstetrics and Gynecology Helmond The Netherlands
Eurofins PAMM Department of Pathology Eindhoven The Netherlands
Ghent University Hospital Department of Pathology Ghent Belgium
GROW School for Oncology and Reproduction Maastricht The Netherlands
Haukeland University Hospital Department of Obstetrics and Gynecology Bergen Norway
Jeroen Bosch Hospital Department of Obstetrics and Gynecology 's Hertogenbosch The Netherlands
Jeroen Bosch Hospital Department of Pathology 's Hertogenbosch The Netherlands
KU Leuven Department of Oncology Leuven Belgium
Maastricht University Medical Center Department of Pathology Maastricht The Netherlands
Máxima Medical Center Veldhoven Department of Obstetrics and Gynecology Veldhoven The Netherlands
Medical Center University of Freiburg Department of Obstetrics and Gynecology Freiburg Germany
PSMAR Hospital del Mar Department of Obstetrics and Gynecology Barcelona Spain
Radboud University Medical Center Department of Obstetrics and Gynecology Nijmegen The Netherlands
Radboud University Medical Center Department of Pathology Nijmegen The Netherlands
University Hospital Brno and Masaryk University Department of Pathology Brno Czech Republic
University of Bergen Department of Clinical Science Center for Cancer Biomarkers Bergen Norway
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016259
- 003
- CZ-PrNML
- 005
- 20250731091640.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijgc.2025.101682 $2 doi
- 035 __
- $a (PubMed)40011117
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Meijs-Hermanns, Puk $u Maastricht University Medical Center, Department of Pathology, Maastricht, The Netherlands
- 245 10
- $a Improving pre-operative binary grading: relevance of p53 and PR expression in grade 2 endometrioid endometrial carcinoma / $c P. Meijs-Hermanns, HMJ. Werner, L. Kooreman, P. Bretová, V. Weinberger, S. Vrede, LSM. Alcala, F. Amant, J. Asberger, M. Bednaříková, D. Boll, CM. Bronkhorst, J. Bulten, A. Gil-Moreno, IS. Haldorsen, J. Hausnerová, J. Huvila, M. Koskas, C. Krakstad, H. Küsters-Vandevelde, G. Mancebo Moreno, X. Matias-Guiu, H. Ngo, BM. Pijlman, M. Santacana, M. Smink, J. Trovik, VMJ. Verhoef, KV. Vijver, DV. Hamont, AAM. van der Wurff, JMA. Pijnenborg, NCM. Visser
- 520 9_
- $a OBJECTIVE: This study aimed to evaluate the association between pre-operative progesterone receptor (PR) and p53 expression and prognosis in pre-operative grade 2 endometrioid endometrial carcinoma compared with grade 1 and grade 3 carcinomas. METHODS: Three European endometrial carcinoma cohort studies were included. Patients with pre-operative grade 2 endometrioid carcinoma and known pre-operative PR and p53 status were included (n = 400), as were patients with pre-operative grade 1 (n = 602) or grade 3 (n = 148) endometrioid carcinomas. Kaplan-Meier and Cox regression analyses were performed to analyze disease-specific and disease-free survival. RESULTS: Patients with pre-operative grade 2 endometrial carcinoma and wild-type p53 plus PR-positive expression showed a similar 7-year disease-specific survival to grade 1 endometrial carcinoma patients (95.8% vs 97.5%, p = .13), while the 7-year disease-specific survival of patients with grade 2 endometrial carcinoma with p53 aberrant and/or negative PR expression (83.5%) was significantly lower (p < .001). The combination of these markers was an independent prognostic factor in multivariate Cox regression analyses. CONCLUSIONS: The prognostic impact of pre-operative p53 and PR expression in patients with grade 2 endometrioid endometrial carcinoma supports a modified binary grading system in which grade 2 patients should be pre-operatively classified as low- or high-grade depending on p53 and PR expression.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory endometria $x patologie $x metabolismus $x chirurgie $x mortalita $7 D016889
- 650 12
- $a nádorový supresorový protein p53 $x metabolismus $x biosyntéza $7 D016159
- 650 12
- $a endometroidní karcinom $x patologie $x metabolismus $x chirurgie $x mortalita $7 D018269
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a receptory progesteronu $x metabolismus $x biosyntéza $7 D011980
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři nad 80 let $7 D000369
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Werner, Henrica M J $u Maastricht University Medical Center, Department of Obstetrics and Gynecology, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht, The Netherlands. Electronic address: erica.werner@mumc.nl
- 700 1_
- $a Kooreman, Loes $u Maastricht University Medical Center, Department of Pathology, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht, The Netherlands
- 700 1_
- $a Bretová, Petra $u University Hospital Brno and Masaryk University, Department of Gynecology and Obstetrics, Brno, Czech Republic
- 700 1_
- $a Weinberger, Vit $u University Hospital Brno and Masaryk University, Department of Gynecology and Obstetrics, Brno, Czech Republic
- 700 1_
- $a Vrede, Stephanie $u Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, The Netherlands
- 700 1_
- $a Alcala, Luthy S M $u Amphia Hospital, Department of Pathology, Breda, The Netherlands
- 700 1_
- $a Amant, Frédéric $u KU Leuven, Department of Oncology, Leuven, Belgium
- 700 1_
- $a Asberger, Jasmin $u Medical Center-University of Freiburg, Department of Obstetrics and Gynecology, Freiburg, Germany
- 700 1_
- $a Bednaříková, Markéta $u University Hospital Brno and Masaryk University, Department of Internal Medicine, Hematology and Oncology, Brno, Czech Republic
- 700 1_
- $a Boll, Dorry $u Catharina Hospital, Department of Gynecology, Eindhoven, The Netherlands
- 700 1_
- $a Bronkhorst, Carolien M $u Jeroen Bosch Hospital, Department of Pathology, 's-Hertogenbosch, The Netherlands
- 700 1_
- $a Bulten, Johan $u Radboud University Medical Center, Department of Pathology, Nijmegen, The Netherlands
- 700 1_
- $a Gil-Moreno, Antonio $u CIBERONC, Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Research, Biomedical Research Group in Gynecology, Barcelona, Spain; CIBERONC, Vall d'Hebron University Hospital, Gynecological Department, Barcelona, Spain
- 700 1_
- $a Haldorsen, Ingfrid S $u University of Bergen, Department of Clinical Science, Center for Cancer Biomarkers, Bergen, Norway; Haukeland University Hospital, Department of Radiology, Mohn Medical Imaging and Visualization Center, Bergen, Norway
- 700 1_
- $a Hausnerová, Jitka $u University Hospital Brno and Masaryk University, Department of Pathology, Brno, Czech Republic
- 700 1_
- $a Huvila, Jutta $u University of Turku, Department of Pathology, Turku, Finland
- 700 1_
- $a Koskas, Martin $u APHP - Bichat Hospital, Department of Obstetrics and Gynecology, Paris, France
- 700 1_
- $a Krakstad, Camilla $u University of Bergen, Department of Clinical Science, Center for Cancer Biomarkers, Bergen, Norway; Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway
- 700 1_
- $a Küsters-Vandevelde, Heidi $u Canisius-Wilhelmina Hospital, Department of Pathology, Nijmegen, The Netherlands
- 700 1_
- $a Mancebo Moreno, Gemma $u PSMAR, Hospital del Mar, Department of Obstetrics and Gynecology, Barcelona, Spain
- 700 1_
- $a Matias-Guiu, Xavier $u CIBERONC, IRBLleida, University of Lleida, Hospital Universitari Arnau de Vilanova, Department of Pathology and Molecular Genetics and Research Laboratory, Lleida, Spain
- 700 1_
- $a Ngo, Huy $u Elkerliek Hospital, Department of Obstetrics and Gynecology, Helmond, The Netherlands
- 700 1_
- $a Pijlman, Brenda M $u Jeroen Bosch Hospital, Department of Obstetrics and Gynecology, 's-Hertogenbosch, The Netherlands
- 700 1_
- $a Santacana, Maria $u Hospital Universitari Arnau de Vilanova, IRBLleida, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, Lleida, Spain
- 700 1_
- $a Smink, Marieke $u Elisabeth-TweeSteden Hospital, Department of Gynecology, Tilburg, The Netherlands
- 700 1_
- $a Trovik, Jone $u University of Bergen, Department of Clinical Science, Center for Cancer Biomarkers, Bergen, Norway; Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway
- 700 1_
- $a Verhoef, Viola M J $u Máxima Medical Center Veldhoven, Department of Obstetrics and Gynecology, Veldhoven, The Netherlands
- 700 1_
- $a Vijver, Koen Van de $u Ghent University Hospital, Department of Pathology, Ghent, Belgium
- 700 1_
- $a Hamont, Dennis van $u Amphia Hospital, Department of Obstetrics and Gynecology, Breda, The Netherlands
- 700 1_
- $a van der Wurff, Anneke A M $u Elisabeth-TweeSteden Hospital, Department of Pathology, Tilburg, The Netherlands
- 700 1_
- $a Pijnenborg, Johanna M A $u Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, The Netherlands
- 700 1_
- $a Visser, Nicole C M $u Eurofins PAMM, Department of Pathology, Eindhoven, The Netherlands
- 773 0_
- $w MED00009896 $t International journal of gynecological cancer $x 1525-1438 $g Roč. 35, č. 4 (2025), s. 101682
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40011117 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091634 $b ABA008
- 999 __
- $a ok $b bmc $g 2366834 $s 1253384
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 35 $c 4 $d 101682 $e 20250207 $i 1525-1438 $m International journal of gynecological cancer $n Int J Gynecol Cancer $x MED00009896
- LZP __
- $a Pubmed-20250708
